Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 0.96 |
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.96 |
| ▸ | OPRK1 known ✓ | P41145 | 5/20 | 0.96 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.96 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.96 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.73 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeine SCHEMBL436793 | 1.00 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922135 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL14371354 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922140 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL13696342 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL8218174 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL10329428 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3257 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL21077535 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1560699 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| US-11904049-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-20 | — | — | US | claimed |
| US-20230063876-A1 | Virus-Like Particle Vaccines for Opioid Drugs | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2023-03-02 | — | — | US | claimed |
| US-20220160618-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2022-05-26 | — | — | US | claimed |
| US-11219600-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2022-01-11 | — | — | US | claimed |
| EP-3932399-A1 | PHARMACEUTICAL FORMULATION | Klaria Pharma Holding AB (SE) | 2022-01-05 | — | — | EP | claimed |
| EP-3634377-B1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2021-07-21 | — | — | EP | claimed |
| US-20200246253-A1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2020-08-06 | — | — | US | claimed |
| US-20030206942-A1 | Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent | MCNEIL-PPC, INC | 2003-11-06 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| WO-2003066029-A2 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246253-A1 | PHARMACEUTICAL FORMULATION | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | OPRD1 422/4885OPRM1 1411/4885OPRK1 1354/4885 |
| US-11219600-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20220160618-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-11904049-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20240165022-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.